Literature DB >> 9488452

The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor.

B L Wagner1, J D Norris, T A Knotts, N L Weigel, D P McDonnell.   

Abstract

Previously, we defined a novel class of ligands for the human progesterone receptor (PR) which function as mixed agonists. These compounds induce a conformational change upon binding the receptor that is different from those induced by agonists and antagonists. This establishes a correlation between the structure of a ligand-receptor complex and its transcriptional activity. In an attempt to define the cellular components which distinguish between different ligand-induced PR conformations, we have determined, by using a mammalian two-hybrid assay, that the nuclear receptor corepressor (NCoR) and the silencing mediator for retinoid and thyroid hormone receptor (SMRT) differentially associate with PR depending upon the class of ligand bound to the receptor. Specifically, we observed that the corepressors preferentially associate with antagonist-occupied PR and that overexpression of these corepressors suppresses the partial agonist activity of antagonist-occupied PR. Binding studies performed in vitro, however, reveal that recombinant SMRT can interact with PR in a manner which is not influenced by the nature of the bound ligand. Thus, the inability of SMRT or NCoR to interact with agonist-activated PR when assayed in vivo may relate more to the increased affinity of PR for coactivators, with a subsequent displacement of corepressors, than to an inherent low affinity for the corepressor proteins. Previous work from other groups has shown that 8-bromo-cyclic AMP (8-bromo-cAMP) can convert the PR antagonist RU486 into an agonist and, additionally, can potentiate the transcriptional activity of agonist-bound PR. In this study, we show that exogenous expression of NCoR or SMRT suppresses all 8-bromo-cAMP-mediated potentiation of PR transcriptional activity. Further analysis revealed that 8-bromo-cAMP addition decreases the association of NCoR and SMRT with PR. Thus, we propose that 8-bromo-cAMP-mediated potentiation of PR transcriptional activity is due, at least in part, to a disruption of the interaction between PR and the corepressors NCoR and SMRT. Cumulatively, these results suggest that NCoR and SMRT expression may play a pivotal role in PR pharmacology.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488452      PMCID: PMC108850          DOI: 10.1128/MCB.18.3.1369

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  45 in total

1.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid.

Authors:  J P Renaud; N Rochel; M Ruff; V Vivat; P Chambon; H Gronemeyer; D Moras
Journal:  Nature       Date:  1995-12-14       Impact factor: 49.962

2.  The partial agonist activity of antagonist-occupied steroid receptors is controlled by a novel hinge domain-binding coactivator L7/SPA and the corepressors N-CoR or SMRT.

Authors:  T A Jackson; J K Richer; D L Bain; G S Takimoto; L Tung; K B Horwitz
Journal:  Mol Endocrinol       Date:  1997-06

3.  In vivo evidence against the existence of antiprogestins disrupting receptor binding to DNA.

Authors:  K Delabre; A Guiochon-Mantel; E Milgrom
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-15       Impact factor: 11.205

4.  Regulation of progesterone receptor-mediated transcription by phosphorylation.

Authors:  L A Denner; N L Weigel; B L Maxwell; W T Schrader; B W O'Malley
Journal:  Science       Date:  1990-12-21       Impact factor: 47.728

5.  Selective effects of 8-Br-cAMP on agonists and antagonists of the glucocorticoid receptor.

Authors:  S Zhang; M Danielsen
Journal:  Endocrine       Date:  1995-01       Impact factor: 3.633

6.  Induction of a novel conformation in the progesterone receptor by ZK299 involves a defined region of the carboxyl-terminal tail.

Authors:  G F Allan; E Lombardi; D Haynes-Johnson; S Palmer; M Kiddoe; P Kraft; C Campen; P Rybczynski; D W Combs; A Phillips
Journal:  Mol Endocrinol       Date:  1996-10

7.  Alteration in the agonist/antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence.

Authors:  N Fujimoto; B S Katzenellenbogen
Journal:  Mol Endocrinol       Date:  1994-03

8.  Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors.

Authors:  C A Beck; N L Weigel; D P Edwards
Journal:  Mol Endocrinol       Date:  1992-04

9.  Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen.

Authors:  M Berry; D Metzger; P Chambon
Journal:  EMBO J       Date:  1990-09       Impact factor: 11.598

Review 10.  The steroid and thyroid hormone receptor superfamily.

Authors:  R M Evans
Journal:  Science       Date:  1988-05-13       Impact factor: 47.728

View more
  55 in total

1.  Molecular determinants of nuclear receptor-corepressor interaction.

Authors:  V Perissi; L M Staszewski; E M McInerney; R Kurokawa; A Krones; D W Rose; M H Lambert; M V Milburn; C K Glass; M G Rosenfeld
Journal:  Genes Dev       Date:  1999-12-15       Impact factor: 11.361

2.  The SMRT corepressor is a target of phosphorylation by protein kinase CK2 (casein kinase II).

Authors:  Y Zhou; W Gross; S H Hong; M L Privalsky
Journal:  Mol Cell Biochem       Date:  2001-04       Impact factor: 3.396

3.  The transcription factor B-Myb is maintained in an inhibited state in target cells through its interaction with the nuclear corepressors N-CoR and SMRT.

Authors:  Xiaolin Li; Donald P McDonnell
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

4.  Isotype-restricted corepressor recruitment: a constitutively closed helix 12 conformation in retinoic acid receptors beta and gamma interferes with corepressor recruitment and prevents transcriptional repression.

Authors:  Behnom Farboud; Herborg Hauksdottir; Yun Wu; Martin L Privalsky
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

5.  The SMRT corepressor is regulated by a MEK-1 kinase pathway: inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export.

Authors:  S H Hong; M L Privalsky
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

6.  Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-dependent transactivation.

Authors:  William H Lagarde; Amanda J Blackwelder; John T Minges; Andrew T Hnat; Frank S French; Elizabeth M Wilson
Journal:  J Biol Chem       Date:  2012-02-13       Impact factor: 5.157

7.  Class I lysine deacetylases facilitate glucocorticoid-induced transcription.

Authors:  Vineela Kadiyala; Nina M Patrick; Wana Mathieu; Rosa Jaime-Frias; Naruekamol Pookhao; Lingling An; Catharine L Smith
Journal:  J Biol Chem       Date:  2013-08-14       Impact factor: 5.157

8.  Signaling by tyrosine kinases negatively regulates the interaction between transcription factors and SMRT (silencing mediator of retinoic acid and thyroid hormone receptor) corepressor.

Authors:  S H Hong; C W Wong; M L Privalsky
Journal:  Mol Endocrinol       Date:  1998-08

9.  Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.

Authors:  Suzanne E Wardell; Ramesh Narayanan; Nancy L Weigel; Dean P Edwards
Journal:  Mol Endocrinol       Date:  2009-12-11

10.  Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor.

Authors:  Myles C Hodgson; Howard C Shen; Anthony N Hollenberg; Steven P Balk
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.